A detailed history of Legal & General Group PLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 96,556 shares of NTLA stock, worth $1.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
96,556
Previous 96,556 -0.0%
Holding current value
$1.16 Million
Previous $1.98 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $32,735 - $45,417
1,660 Added 1.75%
96,556 $1.98 Million
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $166,946 - $226,987
8,339 Added 9.63%
94,896 $2.12 Million
Q1 2024

May 14, 2024

BUY
$23.82 - $32.8 $138,489 - $190,699
5,814 Added 7.2%
86,557 $2.38 Million
Q4 2023

Feb 15, 2024

BUY
$23.16 - $32.34 $13,803 - $19,274
596 Added 0.74%
80,743 $2.46 Million
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $150,258 - $217,546
4,752 Added 6.3%
80,147 $2.53 Million
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $44,227 - $58,872
1,279 Added 1.73%
75,395 $3.07 Million
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $56,576 - $76,149
1,699 Added 2.35%
74,116 $2.76 Million
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $129,286 - $244,052
3,893 Added 5.68%
72,417 $2.53 Million
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $217,405 - $289,094
-4,032 Reduced 5.56%
68,524 $3.83 Million
Q2 2022

Aug 22, 2022

BUY
$38.49 - $76.21 $196,491 - $389,052
5,105 Added 7.57%
72,556 $3.76 Million
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $145,849 - $297,831
2,503 Added 3.85%
67,451 $4.9 Million
Q4 2021

Feb 14, 2022

BUY
$100.76 - $138.36 $799,026 - $1.1 Million
7,930 Added 13.91%
64,948 $7.68 Million
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $1.93 Million - $2.58 Million
14,569 Added 34.32%
57,018 $7.65 Million
Q2 2021

Aug 12, 2021

BUY
$60.88 - $161.91 $304,521 - $809,873
5,002 Added 13.36%
42,449 $6.87 Million
Q1 2021

May 17, 2021

SELL
$46.59 - $83.68 $1.3 Million - $2.34 Million
-27,969 Reduced 42.76%
37,447 $3.01 Million
Q4 2020

Feb 12, 2021

SELL
$18.83 - $63.53 $529,744 - $1.79 Million
-28,133 Reduced 30.07%
65,416 $3.56 Million
Q3 2020

Nov 13, 2020

BUY
$17.47 - $24.93 $611,799 - $873,048
35,020 Added 59.83%
93,549 $1.86 Million
Q2 2020

Aug 14, 2020

BUY
$11.14 - $22.87 $423,041 - $868,488
37,975 Added 184.76%
58,529 $1.23 Million
Q1 2020

May 14, 2020

BUY
$9.44 - $15.58 $85,696 - $141,435
9,078 Added 79.1%
20,554 $286,000
Q4 2019

Feb 13, 2020

BUY
$10.43 - $17.67 $13,830 - $23,430
1,326 Added 13.06%
11,476 $168,000
Q3 2019

Nov 13, 2019

BUY
$13.07 - $18.51 $29,316 - $41,517
2,243 Added 28.37%
10,150 $131,000
Q2 2019

Aug 14, 2019

BUY
$13.88 - $18.41 $28,356 - $37,611
2,043 Added 34.84%
7,907 $121,000
Q4 2018

Feb 15, 2019

BUY
$11.39 - $27.13 $4,977 - $11,855
437 Added 8.05%
5,864 $80,000
Q2 2018

Aug 10, 2018

BUY
$20.02 - $30.79 $46,706 - $71,833
2,333 Added 75.4%
5,427 $149,000
Q1 2018

May 17, 2018

SELL
$19.43 - $34.95 $26,910 - $48,405
-1,385 Reduced 30.92%
3,094 $65,000
Q4 2017

Feb 13, 2018

BUY
$17.39 - $31.12 $77,889 - $139,386
4,479
4,479 $87,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $914M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.